New Delhi, June 30: Prime Minister Narendra Modi on Tuesday headed a high-level meeting to review the planning and preparations for vaccination to combat the coronavirus as and when the vaccine is available. He also threw light on four guiding principles in the management of the vaccination of the virus.
PM Modi noted, "vaccination of India’s vast and diverse population will need to factor in issues including those related to the management of medical supply chains, prioritization of at-risk populations, coordination between different agencies involved in the process, as well as the role of the private sector and civil society in this national endeavor," the statement read.
PM Modi highlighted four guiding principles that will form the foundation of this national effort:
- Vulnerable groups should be identified and prioritized for early vaccination, for example, doctors, nurses, healthcare workers, non-medical frontline corona warriors, and vulnerable people among the general population.
- Vaccination of “anyone, anywhere” should take place i.e. without the imposition of any domicile related restrictions for getting the vaccine.
- Vaccination must be affordable and universal - no person should be left behind.
- The entire process from production to vaccination should be monitored and supported in real-time with the use of technology.
PM Modi "directed officials to evaluate in a broad manner available technology options that can form the backbone of the national endeavor to vaccinate all in the most efficient and timely manner. Prime Minister directed that detailed planning for such large scale vaccination should be undertaken immediately," it further added.
Meanwhile, in a major development, Union Health Ministry's Drug Controller General of India (DCGI) on Tuesday nodded appreciatively for clinical human trials for India's first indigenous COVID-19 vaccine 'Covaxin'. The vaccine is developed by one of India’s leading Bio-Technology company Bharat Biotech in collaboration with the Indian Council of Medical Research & National Institute of Virology.